Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation

Stem Cells

Volumn 34, Issue 2, 2016, Pages 483-492

  Luz Crawford, Patricia ^a,b   Djouad, Farida ^a,b   Toupet, Karine ^a,b   Bony, Claire ^a,b   Franquesa, Marcella ^c   Hoogduijn, Martin J ^c   Jorgensen, Christian ^a,b,d   Noël, Danièle ^a,b,d  

^a HÔPITAL SAINT ELOI   (France)

^b UNIV MONTPELLIER   (France)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LAPEYRONIE HOSPITAL   (France)

Author keywords

Arthritis; Breg; Interleukin 1 receptor antagonist; Macrophage; Mesenchymal stromal cells

Indexed keywords

AGGRECAN; ATAXIN 1; BGLAP PROTEIN; CD19 ANTIGEN; CD45 ANTIGEN; COLLAGEN TYPE 2; COLLAGEN TYPE 2 ALPHA 1 DELTA 2; CYCLOOXYGENASE 2; ENDOGLIN; FATTY ACID BINDING PROTEIN 4; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN LIPASE; MESSENGER RNA; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SYNDECAN 1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTHRITIS; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BONE DENSITY; BONE EROSION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MASS; CARTILAGE CELL; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL STIMULATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFLAMMATION; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PLASMABLAST; POLARIZATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; UNINDEXED SEQUENCE; UPREGULATION; ANIMAL; B LYMPHOCYTE; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLISM; SECRETION (PROCESS);

ANIMALS; ARTHRITIS, EXPERIMENTAL; B-LYMPHOCYTES; CELL DIFFERENTIATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MACROPHAGES; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; TH17 CELLS;

EID: 84958152512     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2254     Document Type: Article

References (42)

1. Koenders MI, van den Berg WB,. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci 2015; 36: 189-195.
2. Siebert S, Tsoukas A, Robertson J, et al., Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev 2015; 67: 280-309.
3. Lamacchia C, Rodriguez E, Palmer G, et al., Articular inflammation is controlled by myeloid cell-derived interleukin 1 receptor antagonist during the acute phase of arthritis in mice. Ann Rheum Dis 2012; 71: 281-287.
4. Hallegua DS, Weisman MH,. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 2002; 61: 960-967.
5. Boni-Schnetzler M, Donath MY,. How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. Br J Clin Pharmacol 2013; 76: 263-268.
6. Burger D, Dayer JM, Palmer G, et al., Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006; 20: 879-896.
7. Ortiz LA, Gambelli F, McBride C, et al., Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100: 8407-8411.
8. Jacques C, Gosset M, Berenbaum F, et al., The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006; 74: 371-403.
9. Ortiz LA, Dutreil M, Fattman C, et al., Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007; 104: 11002-11007.
10. Djouad F, Bouffi C, Ghannam S, et al., Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009; 5: 392-399.
11. Djouad F, Charbonnier LM, Bouffi C, et al., Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032.
12. Shi Y, Su J, Roberts AI, et al., How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012; 33: 136-143.
13. Schena F, Gambini C, Gregorio A, et al., Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 2010; 62: 2776-2786.
14. Maggini J, Mirkin G, Bognanni I, et al., Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010; 5: e9252.
15. Su J, Chen X, Huang Y, et al., Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ 2014; 21: 388-396.
16. Augello A, Tasso R, Negrini SM, et al., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35: 1482-1490.
17. Bouffi C, Bony C, Courties G, et al., IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010; 5: e14247.
18. English K, Ryan JM, Tobin L, et al., Cell contact, prostaglandin E and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3 + regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
19. Selmani Z, Naji A, Zidi I, et al., Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3 + regulatory T cells. Stem Cells 2008; 26: 212-222.
20. Glenn JD, Whartenby KA,. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells 2014; 6: 526-539.
21. Chen M, Su W, Lin X, et al., Adoptive transfer of human gingiva-derived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation. Arthritis Rheum 2013; 65: 1181-1193.
22. Gonzalez-Rey E, Gonzalez MA, Varela N, et al., Human adipose-derived mesenchymal stem cells reduce inflammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 241-248.
23. Zagoura DS, Roubelakis MG, Bitsika V, et al., Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut 2012; 61: 894-906.
24. van Buul GM, Villafuertes E, Bos PK, et al., Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture. Osteoarthritis Cartilage 2012; 20: 1186-1196.
25. Luz-Crawford P, Tejedor G, Mausset-Bonnefont AL et al. Gilz governs the therapeutic potential of mesenchymal stem cells by inducing a switch from pathogenic to regulatory Th17 cells. Arthritis Rheumatol 2015; 67: 1514-1524.
26. Maumus M, Manferdini C, Toupet K, et al., Adipose mesenchymal stem cells protect chondrocytes from degeneration associated with osteoarthritis. Stem Cell Res 2013; 11: 834-844.
27. Toupet K, Maumus M, Luz-Crawford P, et al., Survival and biodistribution of xenogenic adipose mesenchymal stem cells is not affected by the degree of inflammation in arthritis. PLoS One 2015; 10: e0114962.
28. Toda Y, Tsukada J, Misago M, et al., Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. J Immunol 2002; 168: 1984-1991.
29. Franquesa M, Mensah FK, Huizinga R, et al., Human adipose tissue-derived mesenchymal stem cells abrogate plasmablast formation and induce regulatory B cells independently of T helper cells. Stem Cells 2015; 33: 880-891.
30. Mantovani A, Sica A, Sozzani S, et al., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
31. Benoit M, Desnues B, Mege JL,. Macrophage polarization in bacterial infections. J Immunol 2008; 181: 3733-3739.
32. He J, Wang Y, Sun S, et al., Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. Nephrology (Carlton) 2012; 17: 493-500.
33. Zhao MM, Cui JZ, Cui Y, et al., Therapeutic effect of exogenous bone marrow-derived mesenchymal stem cell transplantation on silicosis via paracrine mechanisms in rats. Mol Med Rep 2013; 8: 741-746.
34. Moodley Y, Vaghjiani V, Chan J, et al., Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS One 2013; 8: e69299.
35. Volarevic V, Al-Qahtani A, Arsenijevic N, et al., Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 2010; 43: 255-263.
36. Cho DI, Kim MR, Jeong HY, et al., Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Exp Mol Med 2014; 46: e70.
37. Nemeth K, Leelahavanichkul A, Yuen PS, et al., Bone marrow stromal cells attenuate sepsis via prostaglandin E-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
38. Zhang QZ, Su WR, Shi SH, et al., Human gingiva-derived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells 2010; 28: 1856-1868.
39. Smeets RL, Joosten LA, Arntz OJ, et al., Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum 2005; 52: 2202-2211.
40. Friederichs K, Schmitz J, Weissenbach M, et al., Interleukin-6-induced proliferation of pre-B cells mediated by receptor complexes lacking the SHP2/SOCS3 recruitment sites revisited. Eur J Biochem 2001; 268: 6401-6407.
41. Peng Y, Chen X, Liu Q, et al., Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5 + regulatory B cells producing interleukin 10. Leukemia 2015; 29: 636-646.
42. Franquesa M, Hoogduijn MJ, Bestard O, et al., Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 2012; 3: 212.